Hawthorne Health and RxE2 Partner to Transform Community-Based Clinical Trial Delivery
Hawthorne Health, a leader in community-based clinical trial delivery, and RxE2, a pioneer in pharmacist-led clinical trial services, have announced a groundbreaking strategic partnership aimed at revolutionizing the way clinical trials are conducted in local communities. By combining their expertise and resources, the two organizations are set to expand patient access, enhance trial efficiency, and improve the overall success of clinical research.
A Unified Approach to Clinical Trial Delivery
The new collaboration leverages Hawthorne Health’s network of Good Clinical Practice (GCP)-trained nurses and RxE2’s integration of community pharmacists. Together, they are creating the largest integrated network of community-based clinical trial locations across the country. This partnership brings together the strengths of both organizations, making clinical trials more accessible, efficient, and patient-centric.
With an emphasis on patient convenience, the collaboration aims to streamline logistics, reduce barriers to participation, and provide flexible options that meet the needs of patients in trusted, community-based environments. By utilizing community pharmacies and local healthcare providers, the partnership will reach a larger and more diverse patient population, particularly those who might otherwise face difficulty accessing clinical trials due to geographic or logistical limitations.
“We’re constantly striving to overcome the challenges of patient access and retention in clinical research,” said Josh Rose, CEO of Hawthorne Health. “Our partnership with RxE2 allows us to address these issues directly by bringing clinical trials to patients in their communities. By offering flexible trial options in familiar and convenient settings, we’re not only boosting participation but also ensuring higher-quality data and greater study success.”
Expanding Reach Across the Nation
This partnership represents a major step forward in expanding the reach of clinical trials. By integrating a network of thousands of community pharmacies and trial locations across all 50 states, the partnership is creating a truly nationwide solution for clinical trial delivery. With this unprecedented level of reach, clinical sponsors can access a broader and more diverse patient population, ultimately improving the generalizability and relevance of clinical trial results.
In addition to expanding geographic access, this approach reduces the logistical complexities of traditional clinical trials. With community-based locations, patients can participate in studies without needing to travel long distances to specialized research centers. This eliminates a significant barrier to participation for many individuals, particularly those in rural or underserved areas.
Enhancing Data Quality and Study Success
By bringing clinical trials closer to patients, the partnership is also expected to improve retention rates, which have traditionally been a challenge in clinical research. Patients who participate in trials in their own communities are more likely to stay engaged throughout the study period. Moreover, offering more flexible trial options increases patient satisfaction and overall retention, ultimately resulting in better quality data and higher success rates for sponsors.
“When we think about clinical trials, we often think about the complexity and burden on patients,” said Gerald Finken, CEO of RxE2. “But by working closely with community pharmacists, we are providing participants with a more personal and supportive experience. This partnership allows us to meet patients where they are, in settings they trust, like their local pharmacy. It’s an innovative approach that not only improves patient access but also contributes to a more inclusive and effective clinical trial process.”
The integration of community pharmacists into the clinical trial delivery process is a key innovation in this partnership. Pharmacists, who are trusted healthcare professionals with deep ties to their communities, play a vital role in patient care. By engaging pharmacists in clinical trials, RxE2 helps ensure that participants receive the support and guidance they need throughout the study. Additionally, pharmacists are able to use their expertise in medication management to help ensure patient safety and adherence to trial protocols.
A Patient-Centric Model for Clinical Research
One of the driving forces behind this partnership is the commitment to putting patients first. The clinical trial process can often be intimidating or difficult for participants, particularly when it requires them to travel long distances or navigate complex logistics. By offering trials in local, familiar settings, Hawthorne Health and RxE2 are making participation more convenient and less stressful for patients.
This patient-centric model also takes into account the unique needs and preferences of individual participants. Whether it’s adjusting trial schedules to accommodate work or family commitments, or providing additional support to patients who may need assistance understanding trial protocols, the partnership is dedicated to making the trial experience as flexible and accessible as possible.
Moreover, the integration of AI-enabled technologies enhances this patient-centric approach. By leveraging data and advanced analytics, the partnership can tailor trial options to meet the specific needs of patients, ensuring that each participant receives the most appropriate care and support. This personalized approach not only improves patient satisfaction but also drives better outcomes for clinical trials.
A Vision for the Future of Clinical Trials
The collaboration between Hawthorne Health and RxE2 marks a significant shift in the clinical trial landscape. By focusing on community-based delivery and embracing technology, the partnership is setting new standards for patient access, trial efficiency, and overall success. This approach promises to transform the future of clinical research by making trials more inclusive, flexible, and patient-friendly.
Hawthorne Health and RxE2 are committed to driving innovation in the clinical trial space, and this partnership is just the beginning. As the healthcare landscape continues to evolve, the two organizations are exploring new ways to expand access, improve patient engagement, and accelerate the development of life-saving treatments.
“We believe that the future of clinical trials lies in making them more accessible and patient-friendly,” said Rose. “This partnership with RxE2 is a major step forward in that direction, and we are excited to continue working together to reshape the clinical trial experience for both patients and sponsors.”
Upcoming Presentation at the Annual SCOPE Summit
Hawthorne Health and RxE2 will showcase their innovative approach to community-based clinical trial delivery at the Annual SCOPE Summit, taking place from February 3-6 in Orlando, Florida. Alongside Labcorp, the companies will present a session titled “Bridging the Last Mile: A Hybrid Approach to Patient Access and Retention” on Wednesday, February 5. This session will highlight the integrated approach the companies have developed to enhance patient access and retention through scalable, community-based trial delivery. It is expected to be a key discussion at the summit, offering insights into the future of clinical trials and the importance of patient-centric strategies.
